(Q37481202)

20 August 2017

1 reference

title

Exemestane: a review of its use in postmenopausal women with breast cancer (English)

1 reference

20 August 2017

1 reference

2

Lesley J Scott

1 reference

20 August 2017

1

Emma D Deeks

1 reference

20 August 2017

publication date

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

69

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

889-918

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200969070-00007

20 August 2017

exact match

0 references

cites work

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

12 December 2020

Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane

1 reference

12 December 2020

Management of arthralgias associated with aromatase inhibitor therapy

1 reference

12 December 2020

Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer

1 reference

12 December 2020

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.

1 reference

12 December 2020

Update on aromatase inhibitors in breast cancer

1 reference

12 December 2020

Exemestane for breast cancer prevention: a feasible strategy?

1 reference

12 December 2020

Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy.

1 reference

12 December 2020

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

12 December 2020

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO)

1 reference

12 December 2020

Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.

1 reference

12 December 2020

Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.

1 reference

12 December 2020

A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases

1 reference

12 December 2020

Is there a growing role for endocrine therapy in the treatment of breast cancer?

1 reference

12 December 2020

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women

1 reference

12 December 2020

Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy

1 reference

12 December 2020

Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis

1 reference

12 December 2020

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

12 December 2020

Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.

1 reference

12 December 2020

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

1 reference

12 December 2020

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

12 December 2020

Sex steroid-producing enzymes in human breast cancer

1 reference

12 December 2020

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

12 December 2020

Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?

1 reference

12 December 2020

Oestrogen exposure and breast cancer risk

1 reference

12 December 2020

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids

1 reference

12 December 2020

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

1 reference

12 December 2020

The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial

1 reference

12 December 2020

The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.

1 reference

12 December 2020

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

1 reference

12 December 2020

The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors

1 reference

12 December 2020

Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor

1 reference

12 December 2020

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer

1 reference

12 December 2020

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

1 reference

12 December 2020

Tamoxifen--what next?

1 reference

12 December 2020

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

12 December 2020

Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.

1 reference

12 December 2020

Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients

1 reference

12 December 2020

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients

1 reference

12 December 2020

The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer

1 reference

12 December 2020

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

1 reference

12 December 2020

Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer

1 reference

12 December 2020

Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden.

1 reference

12 December 2020

The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer

1 reference

12 December 2020

The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women

1 reference

12 December 2020

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

12 December 2020

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

1 reference

12 December 2020

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane o

1 reference

12 December 2020

Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer

1 reference

12 December 2020

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer

1 reference

12 December 2020

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy

1 reference

12 December 2020

Steroid metabolism in breast cancer

1 reference

12 December 2020

Aromatase inhibitors in breast cancer

1 reference

12 December 2020

Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer

1 reference

12 December 2020

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

1 reference

12 December 2020

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

12 December 2020

Exemestane: a review of its use in postmenopausal women with advanced breast cancer

1 reference

12 December 2020

Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer

1 reference

12 December 2020

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

12 December 2020

Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors

1 reference

12 December 2020

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

1 reference

12 December 2020

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group

1 reference

12 December 2020

New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials

1 reference

12 December 2020

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole

1 reference

12 December 2020

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

12 December 2020

Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer

1 reference

12 December 2020

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

12 December 2020

10.2165/00003495-200969070-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

20 August 2017

1008954200

0 references

1 reference